Bone Therapeutics SA: Information on the total number of voting rights and shares
REGULATED INFORMATION
Mont-Saint-Guibert, Belgium, 30 September 2022, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares following the conversion of convertible bonds (CBs) issued on 9 June 2022. The following information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the publication of major shareholdings in issuers whose shares are admitted to trading on regulated market.
| Total amount of share capital on 30 August 2022 | EUR 5,352,174 |
| Total number of shares with voting rights on 30 August 2022 | 23,172,152 |
| Total number of new shares issued between 31 August 2022 and 29 September 2022 | 663,819 |
| Total amount of share capital on 29 September 2022 | EUR 5,456,936 |
| Total number of shares with voting rights on 29 September 2022 | 23,835,971 |
| Total number of voting rights (denominator) on 29 September 2022 | 23,835,971 |
| Total number of attributed warrants | 1,197,554 |
| Total number of convertible bonds outstanding | 818 |
| Total number of remaining CB commitments | 70 |
| Total number of shares with voting rights that can be issued following the exercise of the attributed warrants and CB commitments, and the conversion of the convertible bonds | 27,142,985 (1) |
(1)
-
1,197,554 shares could be issued in case all 1,197,554 attributed warrants were exercised.
-
285,714 shares could be issued in case all 800 convertible bonds outstanding, issued in the private placement on 6 May 2020, were converted into shares based on the predetermined conversion price of EUR 7.00.
-
25,142,985 shares could be issued in case all 70 CB commitments subscribed and all 18 convertible bonds outstanding of the ABO CB program signed on 30 May 2022 were exercised and converted into shares based on the conversion price of EUR 0.1715 (95% of the Volume-Weighted-Averaged-Price of Bone Therapeutics’ shares on 28 September 2022).
About Bone Therapeutics
Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. Currently Bone Therapeutics is concentrating specifically on the development of its most advanced clinical asset, the allogeneic cell therapy platform, ALLOB.
Bone Therapeutics’ core technology is based on its cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) which can be stored at the point of use in the hospital. Its leading investigational medicinal product, ALLOB, represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via the Bone Therapeutics’ scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company has initiated patient recruitment for the Phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.